ANAPC15

Across TCGA pan-cancer cohorts, ANAPC15 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated ANAPC15 data layer compared with 3 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ANAPC15 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ANAPC15 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

LIHC, ACC, and KICH are the cancer types where ANAPC15 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.605	0.762	<.001	41	view →
ACC	DFS	Tertile	All	0.213	0.744	<.001	38	view →
KICH	DFS	Quartile	III,IV	0.217	0.895	.011	35	view →
BLCA	DFS	Median	IV	0.444	0.258	.003	20	view →
SKCM	DFS	Quartile	All	0.805	0.673	.017	14	view →
HNSC	DFS	Median	All	0.272	0.371	.004	12	view →
COAD	OS	Median	IV	0.327	0.579	.007	11	view →
THYM	OS	Median	All	0.956	0.593	.007	11	view →
READ	OS	Quartile	III,IV	1.000	0.477	.016	10	view →
UVM	OS	Median	III,IV	0.246	0.836	.003	10	view →
CHOL	DFS	Median	III,IV	0.647	0.127	.006	9	view →
GBM	OS	Quartile	All	0.291	0.480	.011	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 21 lineages.

ANAPC15–LIHC (OS)

Open the LIHC breakdown →